Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product in six additional markets. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, significantly expanding the company's international footprint. The partnerships were established with six separate companies, each dedicated to an individual market, and include minimum purchase quantities that Viromed expects to generate at least 3,000 additional device sales per year.
ViroCAP® is a mobile medical device designed to treat skin conditions using cold atmospheric plasma. It is targeted at hospitals, private practice physicians, and surgically active medical specialists. The device has been well-received in the DACH region (Germany, Austria, and Switzerland) and is now poised for broader adoption across Southern and South-Eastern Europe and the Middle East.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented on the development: "With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks."
This expansion builds on Viromed's existing international network. The company already has exclusive distribution agreements, including a partnership with Korean company UMECO covering ten Asian countries and a distribution agreement with TriPart TITAN GmbH & Co. KG for the Turkish market. These new agreements further solidify Viromed's presence globally.
The strategic importance of these partnerships lies in the growing acceptance of cold plasma technology in medical applications. Cold atmospheric plasma has been shown to have antimicrobial and anti-inflammatory properties, making it valuable in wound care and dermatology. As the technology gains traction, Viromed is positioning itself to capture significant market share in regions where healthcare infrastructure is rapidly developing.
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the development, manufacture, and distribution of medical products through its wholly owned subsidiary Viromed Medical GmbH. The company aims to advance the use of cold plasma technology in medicine and realize the corresponding growth potential. With a broad customer base in the DACH region and beyond, Viromed is well-placed to leverage these new partnerships to drive revenue and market expansion.
The announcement underscores Viromed's commitment to international growth and the increasing demand for innovative medical technologies. By securing distribution channels in diverse markets, Viromed is reducing its dependence on any single region and positioning itself for sustained long-term success.
For more information about Viromed Medical AG and its products, visit www.viromed-medical-ag.de.
